|  |
| --- |
| **Checklist for submitting comments*** Use this comment form and submit it as a **Word document (not a PDF)**.
* Complete the disclosure about links with, or funding from, the tobacco industry.
* Include **page and line number (not section number)** of the text each comment is about.
* Combine all comments from your organisation into 1 response. **We cannot accept more than 1 comments form from each organisation**.
* Do not paste other tables into this table – type directly into the table.
* Ensure each comment stands alone; do not cross-refer within one comment to another comment.
* **Clearly mark any confidential information or other material that you do not wish to be made public with underlining and highlighting. Also, ensure you state in your email to NICE that your submission includes confidential comments.**
* **Do not name or identify any person or include medical information about yourself or another person** from which you or the person could be identified as all such data will be deleted or redacted.
* Spell out any abbreviations you use
* For copyright reasons, **do not include attachments** such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.
* **We do not accept comments submitted after the deadline stated for close of consultation.**

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees. |

|  |  |
| --- | --- |
|  | **Please read the checklist for submitting comments at the end of this form.** We cannot accept forms that are not filled in correctly or arrive after the deadline. In addition to your comments below, we would like to hear your views on these questions:1. Are there any cost saving interventions or examples of innovative approaches that should be considered for inclusion in this guideline?
2. In relation to question 2.1 in section 3.5 of the draft scope: Is this a useful question for NICE to address and if so, how important is it? Are stakeholders aware of evidence that could help us to answer this question? Please send the titles of relevant references rather than copies of these papers.
	1. What is the clinical and cost effectiveness of FDG PET-CT compared to CT with or without bone scintigraphy for the detection of distant metastases in people with suspected advanced breast cancer and does this use of FDG PET-CT improve outcomes?

[Developing NICE guidance: how to get involved](https://www.nice.org.uk/process/pmg22/chapter/introduction) has a list of possible areas for comment on the draft scope.  |
| Organisation name – stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please specify). | [**Insert organisation name or “individual”**] |
| Disclosure(please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry). | **[Insert disclosure here]** |
| Name of person completing form | **[Insert your name here]** |
| **Comment number** | Page numberor **‘general’** for comments on the whole document | **Line****number** or **‘general’** for comments on the whole document | CommentsInsert each comment in a new row.Do not paste other tables into this table, as your comments could get lost – type directly into this table. |
| Example | 003 | 055 | The draft scope currently excludes people who have already been diagnosed. We feel this group should be included because…. |
| Example | 043 | 109 | CONFIDENTIAL: Our unpublished study has shown that [X] is more effective than [Y] |
| 1 |  |  |  |
| 2 |  |  |  |
| 3 |  |  |  |
| 4 |  |  |  |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |
| 9 |  |  |  |
| 10 |  |  |  |

Add extra rows if needed

**Data protection**

The information you submit on this form will be retained and used by NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties. Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted or redacted. The information may appear on the NICE website in due course in which case all personal data will be removed in accordance with NICE policies.

By submitting your data via this form you are confirming that you have read and understood this statement.

For more information about how we process your data, please see our [privacy notice](https://www.nice.org.uk/privacy-notice).